Up to 80% of patients with scleroderma have lung disease, with interstitial lung disease (ILD) being the most common manifestation. Currently, there is no definitive therapy for this condition. The objective of the study is to investigate the use of mycophenolate mofetil (MMF) to treat scleroderma interstitial ILD. We report a retrospective chart review of 17 patients with scleroderma ILD treated with MMF (2 g/day) for at least 12 months. Demographics, bronchoalveolar lavage (BAL) findings, pulmonary physiology and high-resolution computed tomography were recorded at baseline and after 12 and 24 months of therapy. Baseline BAL (n ¼ 12) showed alveolitis (median of 18% neutrophils). Ninety-four percent of subjects had either improved or stable lung function after 12 months of treatment: four improved, 12 were stable and only one worsened. All patients had radiographic abnormalities consistent with ILD. After 12 months of therapy, radiological findings (n ¼ 15) were stable in 11 patients, worse in three, and improved in one. There were no side effects attributable to MMF therapy recorded. Treatment of patients with scleroderma ILD for up to 24 months with MMF was generally associated with stable pulmonary function. These data argue for a prospective trial using MMF to treat scleroderma ILD.
Introduction
Scleroderma (or systemic sclerosis, SSc) has a prevalence of 242 cases per million in the United States. 1 The most common pulmonary manifestations of SSc are interstitial lung disease (ILD) and pulmonary arterial hypertension. [2] [3] [4] The prevalence of ILD in patients with SSc varies from 70% to 90% depending on whether pulmonary function tests or high-resolution computed tomography (HRCT) scans are used to screen for the disease. 5 ILD typically appears early in the course of SSc 5 and, when untreated, tends to progress. 6 It is currently the leading cause of death in patients with SSc. 7 A number of immunosuppressive agents have been used to treat patients with SSc-ILD; the greatest experience is with cyclophosphamide. A large prospective trial has been shown to slow disease progression in a subset of patients. 8 Recently, mycophenolate mofetil (MMF) has been used in a limited number of patients. 9, 10 MMF is the prodrug of mycophenolic acid, which acts to inhibit ''de novo'' synthesis of purine nucleotides. Because lymphocytes are dependent on this pathway for DNA synthesis, MMF inhibits their proliferation. 11 The pathogenesis of SSc-ILD is complex, and likely involves cytokines, growth factors, T and B cells, activated alveolar macrophages, and fibroblasts, which promote an inflammatory and pro-fibrotic environment. [12] [13] [14] Because MMF inhibits many of these mediators and pathways, we considered it to be a reasonable therapy for SSc-ILD. 9 
Methods
Following approval of this study by the Committee on Human Research at the University of California San Francisco, the medical records of patients with SSc referred to the ILD Clinic at the University of California San Francisco between 2000 and 2005 were reviewed. Patients who fulfilled the American College of Rheumatology criteria for the diagnosis of SSc, 15 had evidence of ILD by HRCT and received MMF (2 g/day) were identified as study subjects.
Age, gender, dyspnea, cough, chest pain, symptoms of gastroesophageal reflux disease, smoking status, type of SSc (limited or diffuse), year of SSc diagnosis, and history of previous treatment were recorded. Bronchoalveolar lavage (BAL) was performed according to established protocol, 16 with samples obtained from two locations: (1) the region with the greatest HRCT abnormality and (2) a region with no HRCT abnormality. ''Alveolitis'' was defined as the presence of greater than or equal to 3% neutrophils or 2% eosinophils on BAL cell count and differential. 6, 17, 18 Forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DLCO) were measured using the standard technique. 19, 20 Available pulmonary function tests were abstracted at baseline, 12 and 24 months into therapy. We categorized the response as improved (X10% increase), stable or worse (X10% decrease) according to international standards. 21 Baseline and follow-up HRCT scans were reviewed by two chest radiologists who were blinded to clinical and pulmonary function data as well as the sequence studies were performed (scans were randomly presented as study A or B).
A consensus opinion was reached as to whether studies A and B were the same or whether one was worse than the other. Subsequent decoding of the order of the scans determined whether there was improvement, stabilization or progression of ILD, which was defined by the presence of ground glass opacities, reticulation, traction bronchiectasis and/or honeycombing.
The CT was read as usual interstitial pneumonia (UIP) pattern if the dominant abnormality were bilateral subpleural reticulation with lower lobe predominance and honeycombing, or as non-specific interstitial pneumonia (NSIP) pattern when ground glass opacities, fine reticulation, sparing the peripheral and the absence of honeycombing were the dominant radiographic pattern.
Evaluation for side effects: In general, patients were questioned for symptomatic side effects related to mycophenolate every 3 months (e.g. rash, any infection, diarrhea, gastrointestinal esophageal reflux disease or abdominal pain), and complete blood count checked every 4-8 weeks to rule out anemia or leucopenia. Side effects were recorded in the patient's chart.
Continuous data are expressed as mean, median, standard deviation and maximum/minimum values; binary data are expressed as percentages. Non-parametric methodology was used given the skewed distribution of data points. The primary comparison involved FVC and DLCO measurements at initiation and after 12 months of therapy using the signed rank test. A p value ofo0.05 was considered statistically significant. Only subjects with longitudinal data (i.e. before and after measurements) were included in the comparison analyses. All statistical analysis was performed using SAS v 9.2 (Cary, NC).
Results
Because of the lack of proven therapies for SSc-ILD and intolerance to cyclophosphamide (the most widely used therapy) by many of our patients, we began to consider other therapeutic options for treating SSc-ILD. This report summarizes our experience using MMF as first line therapy for treating SSc-ILD. Eighty-four cases with SSc were reviewed. Of these patients, 38 satisfied the inclusion criteria for SSc-ILD and seventeen had been treated with MMF for at least 12 months time. These 17 patients constituted the study cohort (Tables 1 and 2 ). The average age was 50.879.3 years, women outnumbered men (10-7), most were non-smokers, and most suffered from diffuse cutaneous SSc. SSc was diagnosed a median of 24 months prior to starting MMF, and the median duration of lung involvement was 12 months. All but two patients were symptomatic and all symptomatic patients complained of dyspnea. Thirteen had bibasilar end inspiratory crackles on auscultation.
Twelve patients underwent bronchoscopy with BAL prior to therapy. All had alveolitis, which was most intense in fluid obtained from lung segments with ground glass attenuation on HRCT (18% neutrophils and 6% eosinophils) compared to fluid obtained from lung segments without ground glass attenuation on HRCT (7% neutrophils and 1% eosinophils, p ¼ 0.01, Figure 1) . Interestingly, three of the four patients who improved had the lowest percentage of neutrophils (3%, 9%, and 13%). The fourth patient did not have a BAL performed.
To determine whether therapy with MMF was associated with changes in pulmonary physiology, we computed the change in FVC and DLCO % predicted following 12 and 24 months of therapy. Of 17 patients completing 12 months of MMF therapy, their median change in FVC and DLCO % predicted showed no statistically significant change from baseline (Table 3) . On average, the FVC and DLCO (% predicted) increased by 2.6% (p ¼ 0.22) and 1.4% (p ¼ 0.74), respectively.
Eight patients completed 24 months of follow-up. Similar to their 12-month follow-up, their median change in FVC and DLCO % predicted showed no statistically significant change from baseline (Table 3) . Similarly, on average, the FVC and DLCO % of predicted increased by 2.4% (p ¼ 0.57) and 2% (p ¼ 0.84), respectively. We categorically evaluated the pulmonary function changes of individual patients following 12 months of therapy. By this analysis, we found four subjects (24%) were improved, 12 (70%) remained stable, and one (6%) worsened (Figure 2) .
HRCT images were available in 15 patients. In these patients, the HRCT findings improved in one patient (7%), remained stable in 11 patients (73%), and progressed in three (20%) (Figure 3 ). The single improved HRCT was due to a reduction in the extent of ground glass opacities. The worsening of HRCT's was due to a slight increase in extent of reticular opacities. However, these radiographic changes were subtle as there were no overall change in formal radiologic scores for any individual patient.
In general, patients were screened for side effects every 3 months. No side effects were recorded for any of the patients.
Discussion
ILD is central to the prognosis of patients with SSc. Currently, there is no definitive treatment for this disorder. Our retrospective review of 17 patients with SSc-ILD and evidence of alveolitis treated with MMF shows that the majority had stable pulmonary function and radiographic abnormalities on HRCT following 12 months of therapy. Similar findings were seen in a subgroup that completed 24 months of treatment.
Patients with SSc and alveolitis have been shown to suffer deterioration in lung function and increased mortality compared with SSc patients without alveolitis. 6, 17, 18 All patients in our cohort who had a BAL had alveolitis, suggesting they were a population more likely to have progressive loss of lung function in the absence of treatment. 6 No significant progression in FVC and/or DLCO % predicted was found in these patients either after 12 or 24 months of follow-up, and pulmonary function improved more commonly in patients than those in whom it worsened. Finally, by HRCT most patients remained stable. These observations suggest that MMF therapy may slow the progression of SSc-ILD.
The presence of ground glass opacities on HRCT correlated with an intense alveolitis by BAL. BAL fluid obtained from regions of lung that were ''normal'' by HRCT also had alveolitis, although less severe. In agreement with findings of Clements et al., 22 these results indicate that while ground glass opacities on HRCT are indicative of alveolitis, ''early'', low-grade alveolitis can be present by BAL when it is not evident by HRCT. Therefore, in some instances, the BAL may be more sensitive than HRCT for detecting alveolitis. Treatment of patients with SSc-ILD remains a challenge, as there is no proven therapy with a favorable side effect profile. 23 Recently, the Scleroderma Lung Study 8 compared the efficacy of oral cyclophosphamide to placebo. The mean absolute difference in adjusted 12-month FVC percent predicted between the cyclophosphamide and placebo groups was 2.53%, favoring cyclophosphamide. Adverse events like hematuria, leucopenia and pneumonia were more frequent in cyclophosphamide treated patients. Thus, while cyclophosphamide appears to have a modest beneficial effect for treating SSc-ILD, it may come at the expense of severe side effects and in the opinion of some, it should not yet be consider the routine therapy for these patients. 24 Recently, a pilot study summarizing the use of MMF in SSc-ILD patients suggested it may be effective. 9 However, the sample size was small (n ¼ 5) and follow-up was only 6 months. Similarly, Swigris and coworkers performed a retrospective observational study of 28 patients with ILD and connective tissue disease (nine patients had SSc-ILD) treated with MMF. 10 They showed that values for FVC, TLC, and DLCO remained stable. Most had failed previous glucocorticoid or immunomodulatory therapy and the majority of patients in this study received prednisone in addition to MMF; therefore, it is difficult to determine the beneficial effects of either medication individually.
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In our study, MMF was well tolerated and no patient had adverse effects attributable to the medication. Although side effects are more common when higher (4 3g/d) doses of MMF are used. 25 Few side effects were found when 2 g/d of mycophenolate was used to treat diffuse SSc 26 or lupus nephritis. 25, 27 Additionally, MMF has little ovarian toxicity 28 and it may prevent pneumocystis carinii pneumonia (PCP). 29 Thus, MMF appears to have a more favorable side effect profile than cyclophosphamide and therefore may be better tolerated in SSc-ILD patients. Our study is limited by its retrospective design, small sample size and lack of controls. A larger, prospective, placebo-controlled trial is required to prove the efficacy of MMF. Safety data in our study was not prospectively collected and we relied on retrospective chart review. The occurrence of mild or transient adverse effects may be underestimated. Finally, our patient population consists of patients referred to a tertiary care center and may not represent the general population of SSc-ILD seen in the community setting.
In conclusion, these data suggest that MMF is a safe and well-tolerated therapy for SSc-ILD and that it may slow the course of respiratory decline. Larger, prospective, controlled trials are needed to prove efficacy of MMF in SSc-ILD.
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